Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Hillary Clinton calls out drug maker Gilead over price of hepatitis C pills

Democratic presidential nominee Hillary Clinton said Wednesday her administration will go after drug companies that charge exorbitant prices, singling out the company Gilead, whose hepatitis C drugs cost between $900 and $1,000 per pill in the United States.

Published
19 August 2016
From
UPI.com
German agency criticises European programme for speeding some drug approvals

In pointed remarks, Germany’s cost-effectiveness watchdog has criticised an effort by European regulators to accelerate approval for new medicines by limiting its requirements for evidence. The concerns raised by the agency come as regulators on both side of the Atlantic increasingly look to such approaches to get new drugs to patients with unmet medical needs. At issue is a proposal called adaptive pathways, a term used to describe a method for jumpstarting drug approvals for select patient populations. Two years ago,an EMA pilot programme was launched to compare initial data used for approval with so-called “real world” data, which is subsequently gathered after the medicines are in use.

Published
18 August 2016
From
STAT
New research supports the removal of drug use as a restriction to hepatitis C treatment

New, highly curative hepatitis C therapy is both safe and effective as a treatment option for people who inject drugs receiving opioid substitution therapy according to the results of a world-first clinical trial led by Professor Gregory Dore at the Kirby Institute at UNSW Australia and published today in the Annals of Internal Medicine.

Published
15 August 2016
From
EurekAlert
AbbVie 3D and 2D hepatitis C combos work well for people with HIV and HCV co-infection

AbbVie's paritaprevir-based 3D regimen for hepatitis C virus (HCV) genotype 1 and 2D regimen for genotype 4 were shown to be highly effective and well tolerated for

Published
05 August 2016
By
Liz Highleyman
European Commission Grants Marketing Authorisation for MSD’s ZEPATIER™ (elbasvir/grazoprevir) for the Treatment of Chronic Hepatitis C Infection

MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA (MRK)) today announced that the European Commission has approved ZEPATIER™ (elbasvir/grazoprevir) with or without ribavirin (RBV) for the treatment of chronic hepatitis C virus (HCV) genotype (GT) 1 or GT4 infection in adults.

Published
02 August 2016
From
MSD press release
Addaction publishes major new poll on World Hepatitis Day: 4 in 5 British adults say NHS wrong to restrict access to treatment

Today, as Addaction host a large conference at The British Medical Association in London for World Hepatitis Day, the charity calls for an urgent review of the decision to ration clinically proven treatments to just 10,000 people with the virus per year, limiting access to new drugs that can effectively treat nine out of every ten carriers of the virus.

Published
28 July 2016
From
Addaction
Hepatitis C will be eradicated from Australia in a decade, doctors say

Doctors are predicting the eradication of hepatitis C from Australia by 2026 after a dramatic take-up of new-generation "revolutionary" drugs. Nearly 22,500 patients have commenced treatment since the drugs were listed on the Pharmaceutical Benefits Scheme in March, representing about 10 per cent of all people who are estimated to be living with hepatitis C.

Published
28 July 2016
From
Sydney Morning Herald
NHS England tried to sabotage hepatitis C drugs release because it couldn't afford them, doctors claim

NHS England tried to sabotage the release of hepatitis C drugs because it couldn't afford them, it has been claimed. Under current procedures, drugs approved by Nice typically become widely available to NHS patients after a statutory period of 90 days. However, the BMJ claims: “In an apparent panic over high prices and affordability, NHS England deployed many delaying tactics to block timely access to the hepatitis C drugs.”

Published
28 July 2016
From
The Independent
CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX® for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A)

AbbVie announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a positive opinion for the use of 12 weeks of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) with ribavirin (RBV) in genotype 4 (GT4) chronic hepatitis C virus (HCV) infected adult patients with compensated cirrhosis (Child-Pugh A). VIEKIRAX with RBV is currently approved in the European Union for GT4 patients with compensated cirrhosis for 24 weeks.

Published
26 July 2016
From
AbbVie press release
Sofosbuvir/velpatasvir shows high cure rate in HIV/HCV co-infection study

The once-daily co-formulation of sofosbuvir and velpatasvir was highly effective against all hepatitis C virus (HCV) genotypes in people with HIV/HCV co-infection and was safe and well

Published
21 July 2016
By
Liz Highleyman
← First12345...80Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close